Apsen Farmaceutica S.A.
14
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
28.6%
4 terminated/withdrawn out of 14 trials
66.7%
-19.8% vs industry average
50%
7 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
Role: lead
Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder
Role: lead
Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction
Role: lead
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Role: lead
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Role: lead
Phase I Study to Evaluate the Safety of Dexibuprofen 200mg Under Fasting and Fed Conditions
Role: lead
Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction
Role: lead
Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin
Role: lead
Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS
Role: lead
Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease
Role: lead
Prevention of Complications (SARS-CoV-2): Clinical Study
Role: collaborator
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)
Role: lead
Phase I Study to Evaluate the Safety of Dexibuprofen 300mg Under Fasting and Fed Conditions
Role: lead
Identification of Scores Associated With a Favorable Clinical Response With Thiopurines in IBD Patients
Role: collaborator
All 14 trials loaded